Acrolein-mediated neuronal cell death and alpha-synuclein aggregation: Implications for Parkinson's disease

Mol Cell Neurosci. 2018 Apr:88:70-82. doi: 10.1016/j.mcn.2018.01.006. Epub 2018 Feb 3.

Abstract

Growing evidence suggests that oxidative stress plays a critical role in neuronal destruction characteristic of Parkinson's disease (PD). However, the molecular mechanisms of oxidative stress-mediated dopaminergic cell death are far from clear. In the current investigation, we tested the hypothesis that acrolein, an oxidative stress and lipid peroxidation (LPO) product, is a key factor in the pathogenesis of PD. Using a combination of in vitro, in vivo, and cell free models, coupled with anatomical, functional, and behavioral examination, we found that acrolein was elevated in 6-OHDA-injected rats, and behavioral deficits associated with 6-OHDA could be mitigated by the application of the acrolein scavenger hydralazine, and mimicked by injection of acrolein in healthy rats. Furthermore, hydralazine alleviated neuronal cell death elicited by 6-OHDA and another PD-related toxin, rotenone, in vitro. We also show that acrolein can promote the aggregation of alpha-synuclein, suggesting that alpha-synuclein self-assembly, a key pathological phenomenon in human PD, could play a role in neurotoxic effects of acrolein in PD models. These studies suggest that acrolein is involved in the pathogenesis of PD, and the administration of anti-acrolein scavengers such as hydralazine could represent a novel strategy to alleviate tissue damage and motor deficits associated with this disease.

Keywords: 3-HPMA; Aldehyde; Inflammation; Lipid peroxidation; Oxidative stress.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Acrolein / pharmacology*
  • Animals
  • Cell Death / drug effects*
  • Cell Line
  • Dopamine / metabolism
  • Dopaminergic Neurons / drug effects*
  • Dopaminergic Neurons / metabolism
  • Oxidative Stress / drug effects
  • Parkinson Disease / drug therapy
  • Parkinson Disease / metabolism*
  • Rats
  • Spinal Cord Injuries / drug therapy
  • Spinal Cord Injuries / metabolism
  • Substantia Nigra / drug effects
  • Substantia Nigra / metabolism
  • alpha-Synuclein / metabolism*

Substances

  • alpha-Synuclein
  • Acrolein
  • Dopamine